CDKN2A and leukemia: CDKN2A gene can control cell cycle through the P53-MDM pathway; it might be attributed to the fact that CDKN2A deletion cooperates with the TP53 deletion to enhance the aggressiveness of the disease by strongly increasing the self-renewal capacity of leukemia cells, but there is no theory to support this hypothesis.